ProShare Advisors
GLUE icon

ProShare Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

ProShare Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Buy
12,183
+809
+7% +$15.5K ﹤0.01% 1580
2025
Q4 		$178K Buy
11,374
+1,199
+12% +$16.2K ﹤0.01% 1753
2025
Q3 		$75.4K Sell
10,175
-1,686
-14% -$8.93K ﹤0.01% 1884
2025
Q2 		$53.5K Buy
11,861
+149
+1% +$665 ﹤0.01% 1983
2025
Q1 		$54.3K Sell
11,712
-2,829
-19% -$17.3K ﹤0.01% 1944
2024
Q4 		$101K Buy
+14,541
New +$109K ﹤0.01% 2072
2022
Q2 		– Sell
-10,230
Closed -$144K – 1926
2022
Q1 		$144K Buy
+10,230
New +$142K ﹤0.01% 1963

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return